The Global Market for Molecular Cytogenetics is Projected to Reach US$2.3 Billion by 2022
Unmet Diagnostic Needs in Cancer & Genetic
Disorders to Drive the Molecular Cytogenetics Market, According to a New Report
by Global Industry Analysts, Inc.
GIA
launches comprehensive analysis of industry segments, trends, growth drivers,
market share, size and demand forecasts on the global Molecular Cytogenetics market.
The
global market for Molecular Cytogenetics
is projected to reach US$2.3 billion by 2022, driven by the rising
demand for rapid and accurate diagnostic techniques which involve detection of
chromosomal anomalies that predispose patient groups to various diseases.
Molecular
Cytogenetics refers to extensive studies of chromosomal variation and
abnormalities, and their relation to disease. Cytogenetics plays an important
role in identification of genetic predisposition to disease and also a person’s
reaction to a certain drug. Simpler
cytogenetic technologies, such as Capillary Electrophoresis (CE), first
generation amplification, and PCR (Polymerase Chain Reaction) have given way to
advancements such as Fluorescence in Situ Hybridization (FISH) as well as
array-based technologies, in particular array-based Comparative Genome
Hybridization (aCGH). Advanced molecular cytogenetic technologies have assumed an
extremely significant role in medical research. aCGH as a high-resolution tool
that offers the unique ability of performing thousands of experiments in one
array is fast replacing FISH technology, with advantages in terms of rapid and
accurate diagnosis.
Cytogenetic techniques aid
pathologists in diagnosis and prognosis related to solid tumors and
hematological malignancies. With the increasing incidence of cancer worldwide,
the scope of molecular cytogenetics is increasing. Better understanding of the
relation between certain chromosomal anomalies and cancers has necessitated
their detection through multiplex or multicolor Fluorescence
In Situ Hybridization (multiplex FISH). Whole-genome tools, such as
microarrays and next-generation sequencing (NGS), enable the study of the whole
genome from a few malignant cells, at a resolution and precision high enough to
detect abnormalities and consider potential rearrangements. Apart from
improving quality of care and treatment, molecular cytogenetics also assist physicians
in developing personalized therapies by leveraging the concepts of
pharmacogenomics and pharmacogenetics. Demand for higher-resolution chromosomal
analysis stands to benefit from research studies linking chromosomal
abnormality to autism, schizophrenia, as well as cancer.
As stated by the new
market research report on Molecular
Cytogenetics, the United States
represents the largest market worldwide. Asia-Pacific ranks as the fastest
growing market with a CAGR of 27.4% over the analysis period. The growth in the
region is led by growing population, high disease prevalence, unmet needs in
effective disease diagnosis, rise in chromosome abnormalities due to unchecked
and uncontrolled pollution in emerging economies, and growing per capita
healthcare spending in developing countries like China and India.
Major
players covered in the report include Abbott Molecular Inc., Agilent
Technologies Inc., Affymetrix Inc., Applied Spectral Imaging, Biological
Industries, Bio-Rad Laboratories Inc., CytoTest Inc., Cytognomix Inc., Illumina
Inc., Leica Biosystems Nussloch GmbH, Oxford Gene Technology, PerkinElmer Inc.,
Roche NimbleGen Inc., SciGene Corporation, and Thermo Fisher Scientific, Inc.
The
research report titled "Molecular Cytogenetics: A Global Strategic Business
Report" announced by Global
Industry Analysts Inc., provides a comprehensive review of market trends, growth
drivers, mergers and acquisitions, and other strategic industry activities of
major companies worldwide. The report provides market estimates and projections
for geographic markets, such as the US, Canada, Japan, Europe (France, Germany,
Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific (China and Rest of
Asia-Pacific) and Rest of World. Technology segments analyzed for the market
include FISH (Fluorescent In Situ Hybridization) and Array-based Technologies.
Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA,
All Rights Reserved.
Comments
Post a Comment